Overview

A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasis

Status:
Not yet recruiting

Trial end date:
2026-05-24

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate the efficacy of apremilast in children and adolescents (ages 6 through 17 years) with moderate to severe plaque psoriasis.

Phase:

Phase 3

Details

Lead Sponsor:

Amgen

Treatments:

Apremilast